1. Home
  2. YSG vs OBIO Comparison

YSG vs OBIO Comparison

Compare YSG & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YSG

Yatsen Holding Limited

HOLD

Current Price

$3.11

Market Cap

288.0M

ML Signal

HOLD

Logo Orchestra BioMed Holdings Inc.

OBIO

Orchestra BioMed Holdings Inc.

HOLD

Current Price

$4.10

Market Cap

240.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YSG
OBIO
Founded
2016
2017
Country
China
United States
Employees
N/A
86
Industry
Package Goods/Cosmetics
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
288.0M
240.7M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
YSG
OBIO
Price
$3.11
$4.10
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$14.25
AVG Volume (30 Days)
243.9K
239.6K
Earning Date
05-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.13
EPS
N/A
N/A
Revenue
N/A
$33,482,000.00
Revenue This Year
$23.08
N/A
Revenue Next Year
$9.45
$12.43
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1169.22
52 Week Low
$2.15
$2.20
52 Week High
$11.04
$5.42

Technical Indicators

Market Signals
Indicator
YSG
OBIO
Relative Strength Index (RSI) 52.83 54.08
Support Level $2.76 $4.07
Resistance Level $3.23 $4.18
Average True Range (ATR) 0.39 0.17
MACD 0.02 0.02
Stochastic Oscillator 51.34 86.49

Price Performance

Historical Comparison
YSG
OBIO

About YSG Yatsen Holding Limited

Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands. Geographically, company operates in PRC, Europe and US regions.

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.

Share on Social Networks: